343 related articles for article (PubMed ID: 33540469)
1. Chemogenetic approaches to identify metabolically important GPCR signaling pathways: Therapeutic implications.
Meister J; Wang L; Pydi SP; Wess J
J Neurochem; 2021 Aug; 158(3):603-620. PubMed ID: 33540469
[TBL] [Abstract][Full Text] [Related]
2. Use of DREADD Technology to Identify Novel Targets for Antidiabetic Drugs.
Wang L; Zhu L; Meister J; Bone DBJ; Pydi SP; Rossi M; Wess J
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():421-440. PubMed ID: 32746768
[TBL] [Abstract][Full Text] [Related]
3. A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways.
Hu J; Stern M; Gimenez LE; Wanka L; Zhu L; Rossi M; Meister J; Inoue A; Beck-Sickinger AG; Gurevich VV; Wess J
J Biol Chem; 2016 Apr; 291(15):7809-20. PubMed ID: 26851281
[TBL] [Abstract][Full Text] [Related]
4. DREADD: a chemogenetic GPCR signaling platform.
Zhu H; Roth BL
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25522378
[TBL] [Abstract][Full Text] [Related]
5. Utilizing Designed Receptors Exclusively Activated by Designer Drug Chemogenetic Tools to Identify Beneficial G Protein-Coupled Receptor Signaling for Fibrosis.
Zhang J; Vardy E; Muise ES; Wang TM; Visconti R; Vadlamudi A; Pinto S; Peier AM
J Pharmacol Exp Ther; 2020 Nov; 375(2):357-366. PubMed ID: 32848074
[TBL] [Abstract][Full Text] [Related]
6. Use of Designer G Protein-Coupled Receptors to Dissect Metabolic Pathways.
Wess J
Trends Endocrinol Metab; 2016 Sep; 27(9):600-603. PubMed ID: 27381463
[TBL] [Abstract][Full Text] [Related]
7. Side-by-side comparison of the effects of Gq- and Gi-DREADD-mediated astrocyte modulation on intracellular calcium dynamics and synaptic plasticity in the hippocampal CA1.
Van Den Herrewegen Y; Sanderson TM; Sahu S; De Bundel D; Bortolotto ZA; Smolders I
Mol Brain; 2021 Sep; 14(1):144. PubMed ID: 34544455
[TBL] [Abstract][Full Text] [Related]
8. Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution.
Pei Y; Dong S; Roth BL
Curr Protoc Neurosci; 2010 Jan; Chapter 4():Unit 4.33. PubMed ID: 20066658
[TBL] [Abstract][Full Text] [Related]
9. Virus-Mediated Expression of DREADDs for In Vivo Metabolic Studies.
Rossi M; Cui Z; Nakajima K; Hu J; Zhu L; Wess J
Methods Mol Biol; 2015; 1335():205-21. PubMed ID: 26260603
[TBL] [Abstract][Full Text] [Related]
10. Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.
Burnett CJ; Krashes MJ
J Neurosci; 2016 Sep; 36(36):9268-82. PubMed ID: 27605603
[TBL] [Abstract][Full Text] [Related]
11. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
Urban DJ; Roth BL
Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
[TBL] [Abstract][Full Text] [Related]
12. Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.
Zhu H; Aryal DK; Olsen RH; Urban DJ; Swearingen A; Forbes S; Roth BL; Hochgeschwender U
Genesis; 2016 Aug; 54(8):439-46. PubMed ID: 27194399
[TBL] [Abstract][Full Text] [Related]
13. Selective activation of G
Wang L; Pydi SP; Cui Y; Zhu L; Meister J; Gavrilova O; Berdeaux R; Fortin JP; Bence KK; Vernochet C; Wess J
Mol Metab; 2019 Sep; 27():83-91. PubMed ID: 31272886
[TBL] [Abstract][Full Text] [Related]
14. Adipocyte G Protein-Coupled Receptors as Potential Targets for Novel Antidiabetic Drugs.
Liu L; Wess J
Diabetes; 2023 Jul; 72(7):825-834. PubMed ID: 37339353
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Metabolic Roles of G Proteins of the Gi Family Studied With Novel Mouse Models.
Wess J
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34871353
[TBL] [Abstract][Full Text] [Related]
16. Novel designer receptors to probe GPCR signaling and physiology.
Wess J; Nakajima K; Jain S
Trends Pharmacol Sci; 2013 Jul; 34(7):385-92. PubMed ID: 23769625
[TBL] [Abstract][Full Text] [Related]
17. How structure informs and transforms chemogenetics.
Roth BL
Curr Opin Struct Biol; 2019 Aug; 57():9-16. PubMed ID: 30818201
[TBL] [Abstract][Full Text] [Related]
18. Engineered GPCRs as tools to modulate signal transduction.
Pei Y; Rogan SC; Yan F; Roth BL
Physiology (Bethesda); 2008 Dec; 23():313-21. PubMed ID: 19074739
[TBL] [Abstract][Full Text] [Related]
19. The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.
Campbell EJ; Marchant NJ
Br J Pharmacol; 2018 Apr; 175(7):994-1003. PubMed ID: 29338070
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity.
Oliveira de Souza C; Sun X; Oh D
Front Endocrinol (Lausanne); 2021; 12():715877. PubMed ID: 34497585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
